GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Haemonetics Corp (NYSE:HAE) » Definitions » PB Ratio
中文

Haemonetics (Haemonetics) PB Ratio : 4.64 (As of Apr. 25, 2024)


View and export this data going back to 1991. Start your Free Trial

What is Haemonetics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-25), Haemonetics's share price is $86.22. Haemonetics's Book Value per Share for the quarter that ended in Dec. 2023 was $18.58. Hence, Haemonetics's PB Ratio of today is 4.64.

The historical rank and industry rank for Haemonetics's PB Ratio or its related term are showing as below:

HAE' s PB Ratio Range Over the Past 10 Years
Min: 1.84   Med: 4.26   Max: 11.9
Current: 4.64

During the past 13 years, Haemonetics's highest PB Ratio was 11.90. The lowest was 1.84. And the median was 4.26.

HAE's PB Ratio is ranked worse than
76.63% of 796 companies
in the Medical Devices & Instruments industry
Industry Median: 2.2 vs HAE: 4.64

During the past 12 months, Haemonetics's average Book Value Per Share Growth Rate was 20.80% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 11.60% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 3.30% per year. During the past 10 years, the average Book Value Per Share Growth Rate was -0.70% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Haemonetics was 29.40% per year. The lowest was -6.20% per year. And the median was 7.55% per year.

Back to Basics: PB Ratio


Haemonetics PB Ratio Historical Data

The historical data trend for Haemonetics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haemonetics PB Ratio Chart

Haemonetics Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.68 8.54 7.72 4.31 5.10

Haemonetics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.11 5.10 4.99 5.09 4.60

Competitive Comparison of Haemonetics's PB Ratio

For the Medical Instruments & Supplies subindustry, Haemonetics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Haemonetics's PB Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Haemonetics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Haemonetics's PB Ratio falls into.



Haemonetics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Haemonetics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=86.22/18.575
=4.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Haemonetics  (NYSE:HAE) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Haemonetics PB Ratio Related Terms

Thank you for viewing the detailed overview of Haemonetics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Haemonetics (Haemonetics) Business Description

Traded in Other Exchanges
Address
125 Summer Street, Boston, MA, USA, 02110
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
Executives
Stewart W Strong officer: President, Global Hospital C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Anila Lingamneni officer: EVP, Chief Technology Officer HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Charles J Dockendorff director COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Diane M Bryant director 2200 MISSION COLLEGE BLVD, SANTA CLARA CA 95054
Josep Llorens officer: EVP, Global Manufacturing HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Michelle L Basil officer: EVP and General Counsel HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Farris Maryanne Maunsell officer: VP, Chief Accounting Officer C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Roy Galvin officer: President, Global Plasma & BC C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Laurie A. Miller officer: SVP, Human Resources C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Mark W Kroll director PO BOX 23, CRYSTAL BAY MN 55323
Dan Goldstein officer: VP, Corporate Controller HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Christopher Simon, director, officer: President & CEO HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
James Darecca officer: EVP, Chief Financial Officer C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Burke William P. Mr. officer: EVP, Chief Financial Officer HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Lloyd Emerson Johnson director 16737 NEW PROVIDENCE LANE, CHARLOTTE NC 28277